166 related articles for article (PubMed ID: 18401866)
41. Localization of cathepsin K in human osteoclasts by in situ hybridization and immunohistochemistry.
Littlewood-Evans A; Kokubo T; Ishibashi O; Inaoka T; Wlodarski B; Gallagher JA; Bilbe G
Bone; 1997 Feb; 20(2):81-6. PubMed ID: 9028530
[TBL] [Abstract][Full Text] [Related]
42. Biorecognition of HPMA copolymer-adriamycin conjugates by lymphocytes mediated by synthetic receptor binding epitopes.
Omelyanenko V; Kopecková P; Prakash RK; Ebert CD; Kopecek J
Pharm Res; 1999 Jul; 16(7):1010-9. PubMed ID: 10450924
[TBL] [Abstract][Full Text] [Related]
43. Cathepsin K inhibitors prevent matrix-derived growth factor degradation by human osteoclasts.
Fuller K; Lawrence KM; Ross JL; Grabowska UB; Shiroo M; Samuelsson B; Chambers TJ
Bone; 2008 Jan; 42(1):200-11. PubMed ID: 17962093
[TBL] [Abstract][Full Text] [Related]
44. Polymer conjugates of the highly potent cytostatic drug 2-pyrrolinodoxorubicin.
Studenovsky M; Ulbrich K; Ibrahimova M; Rihova B
Eur J Pharm Sci; 2011 Jan; 42(1-2):156-63. PubMed ID: 21075206
[TBL] [Abstract][Full Text] [Related]
45. Activity of lysosomal and nonlysosomal proteases of fibrosarcoma induced by methylcholanthrene.
Gołaszewski Z; Sobolewski K; Gołaszewska J; Pałka J; Ostrowska H
Rocz Akad Med Bialymst; 1997; 42(1):213-7. PubMed ID: 9581482
[TBL] [Abstract][Full Text] [Related]
46. A prostate-specific antigen activated N-(2-hydroxypropyl) methacrylamide copolymer prodrug as dual-targeted therapy for prostate cancer.
Chandran SS; Nan A; Rosen DM; Ghandehari H; Denmeade SR
Mol Cancer Ther; 2007 Nov; 6(11):2928-37. PubMed ID: 18025277
[TBL] [Abstract][Full Text] [Related]
47. Lysosomal cysteine and aspartic proteinases, acid phosphatase, and an endogenous cysteine proteinase inhibitor, cystatin-beta, in rat osteoclasts.
Ohsawa Y; Nitatori T; Higuchi S; Kominami E; Uchiyama Y
J Histochem Cytochem; 1993 Jul; 41(7):1075-83. PubMed ID: 8515049
[TBL] [Abstract][Full Text] [Related]
48. Characterization of the necrotic cleavage of poly(ADP-ribose) polymerase (PARP-1): implication of lysosomal proteases.
Gobeil S; Boucher CC; Nadeau D; Poirier GG
Cell Death Differ; 2001 Jun; 8(6):588-94. PubMed ID: 11536009
[TBL] [Abstract][Full Text] [Related]
49. Degradation of ricin A chain by endosomal and lysosomal enzymes--the protective role of ricin B chain.
Bilge A; Howell-Clark J; Ramakrishnan S; Press OW
Ther Immunol; 1994 Aug; 1(4):197-204. PubMed ID: 7584495
[TBL] [Abstract][Full Text] [Related]
50. Cytoplasmic delivery and nuclear targeting of synthetic macromolecules.
Jensen KD; Nori A; Tijerina M; Kopecková P; Kopecek J
J Control Release; 2003 Feb; 87(1-3):89-105. PubMed ID: 12618026
[TBL] [Abstract][Full Text] [Related]
51. Pharmacokinetic and biodistribution studies of a bone-targeting drug delivery system based on N-(2-hydroxypropyl)methacrylamide copolymers.
Wang D; Sima M; Mosley RL; Davda JP; Tietze N; Miller SC; Gwilt PR; Kopecková P; Kopecek J
Mol Pharm; 2006; 3(6):717-25. PubMed ID: 17140259
[TBL] [Abstract][Full Text] [Related]
52. Cellular Uptake and Intracellular Trafficking of Poly( N-(2-Hydroxypropyl) Methacrylamide).
Battistella C; Guiet R; Burri O; Seitz A; Escrig S; Knott GW; Meibom A; Klok HA
Biomacromolecules; 2019 Jan; 20(1):231-242. PubMed ID: 30395472
[TBL] [Abstract][Full Text] [Related]
53. Involvement of lysosomal cathepsins in the cleavage of DNA topoisomerase I during necrotic cell death.
Pacheco FJ; Servin J; Dang D; Kim J; Molinaro C; Daniels T; Brown-Bryan TA; Imoto-Egami M; Casiano CA
Arthritis Rheum; 2005 Jul; 52(7):2133-45. PubMed ID: 15986368
[TBL] [Abstract][Full Text] [Related]
54. Lysosomal trafficking and cysteine protease metabolism confer target-specific cytotoxicity by peptide-linked anti-CD30-auristatin conjugates.
Sutherland MS; Sanderson RJ; Gordon KA; Andreyka J; Cerveny CG; Yu C; Lewis TS; Meyer DL; Zabinski RF; Doronina SO; Senter PD; Law CL; Wahl AF
J Biol Chem; 2006 Apr; 281(15):10540-7. PubMed ID: 16484228
[TBL] [Abstract][Full Text] [Related]
55. Inhibition of Drynariae Rhizoma extracts on bone resorption mediated by processing of cathepsin K in cultured mouse osteoclasts.
Jeong JC; Kang SK; Youn CH; Jeong CW; Kim HM; Lee YC; Chang YC; Kim CH
Int Immunopharmacol; 2003 Nov; 3(12):1685-97. PubMed ID: 14555293
[TBL] [Abstract][Full Text] [Related]
56. Effect of E. faecalis on the release of serine proteases elastase and cathepsin G, and collagenase-2 (MMP-8) by human polymorphonuclear leukocytes (PMNs).
Reynaud af Geijersstam A; Sorsa T; Stackelberg S; Tervahartiala T; Haapasalo M
Int Endod J; 2005 Sep; 38(9):667-77. PubMed ID: 16104981
[TBL] [Abstract][Full Text] [Related]
57. Biodistribution and antitumour efficacy of long-circulating N-(2-hydroxypropyl)methacrylamide copolymer-doxorubicin conjugates in nude mice.
Shiah JG; Dvorák M; Kopecková P; Sun Y; Peterson CM; Kopecek J
Eur J Cancer; 2001 Jan; 37(1):131-9. PubMed ID: 11165140
[TBL] [Abstract][Full Text] [Related]
58. Anticancer and antiangiogenic activity of HPMA copolymer-aminohexylgeldanamycin-RGDfK conjugates for prostate cancer therapy.
Greish K; Ray A; Bauer H; Larson N; Malugin A; Pike D; Haider M; Ghandehari H
J Control Release; 2011 May; 151(3):263-70. PubMed ID: 21223983
[TBL] [Abstract][Full Text] [Related]
59. Feasibility of using a bone-targeted, macromolecular delivery system coupled with prostaglandin E(1) to promote bone formation in aged, estrogen-deficient rats.
Miller SC; Pan H; Wang D; Bowman BM; Kopecková P; Kopecek J
Pharm Res; 2008 Dec; 25(12):2889-95. PubMed ID: 18758923
[TBL] [Abstract][Full Text] [Related]
60. Doxorubicin bound to a HPMA copolymer carrier through hydrazone bond is effective also in a cancer cell line with a limited content of lysosomes.
Ríhová B; Etrych T; Pechar M; Jelínková M; Stastný M; Hovorka O; Kovár M; Ulbrich K
J Control Release; 2001 Jul; 74(1-3):225-32. PubMed ID: 11489498
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
